John Higuchi is CEO of Aciont. Higuchi is a former VP of Business Development and Corporate Treasurer for Lipocine (Nasdaq: LPCN) and currently serves on its Board. Lipocine is a late clinical staged, oral drug delivery company that has filed an NDA for the first oral drug to treat hypogonadism in men and it has an oral drug for the prevention of pre-term birth entering late stage clinical development. Higuchi also is a co-founder and Board member of Spriaso, LLC, which has an FDA approved combination drug product for respiratory therapy and has other primary care products under development. He received his BS degree in Chemistry at Hope College and his MBA and MS in Information Systems from The George Washington University.